AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

181.100

-0.890-0.49%

Volume:126.20K

Turnover:23.08M

Market Cap:86.73B

PE:-23.56

High:185.000

Open:185.000

Low:180.290

Close:181.990

52wk High:216.734

52wk Low:88.830

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.05

T/O Rate:0.03%

Dividend:4.19

Dividend Rate:2.32%

EPS(TTM):-7.685

EPS(LYR):-7.684

ROE:-15.83%

ROA:7.26%

PB:4.08

PE(LYR):-23.57

Loading ...

Overview Company News Filings

CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value

Simply Wall St.

CSL Stock And 2 Australian Dividend Shares Backed By Earnings

Simply Wall St.

Australian Shares Log Best Month Since February as Rate-hike Worries Ease

CSL Stock And QBE Shares For Dividend Income Above 3%

Simply Wall St.

Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

Simply Wall St.

Asia Morning Call-Global Markets

ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally

MT Newswires Live

Australia's CSL Rises on Launching Trials for Patented Manufacturing Process

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

MT Newswires Live

Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement

Horizon 2 Technology Enables Greater Immunoglobulin Production

THOMSON REUTERS

To Launch Clinical Trials for Horizon 2 Immunoglobulin Process

THOMSON REUTERS

CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing

THOMSON REUTERS

To Seek FDA and Ema Approval for Horizon 2

THOMSON REUTERS

CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process

THOMSON REUTERS

To Commence Horizon 2 Clinical Activities in Mid-2027

THOMSON REUTERS

ASX Dividend Stocks For Steady Income in Uncertain Markets

Simply Wall St.

CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

MT Newswires Live

Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period

THOMSON REUTERS

CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/CSL.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":181.1,"timestamp":1791416559214,"preClose":181.99,"halted":0,"volume":126202,"delay":0,"changeRate":-0.0048903785922304235,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.685440608074044,"marketStatus":"Trading","change":-0.89,"latestTime":"10-08 10:42:40 AEDT","open":185,"high":185,"low":180.29,"amount":23077919,"amplitude":0.025881,"askPrice":181.16,"askSize":18,"bidPrice":181.11,"bidSize":38,"shortable":3,"etf":0,"ttmEps":-7.685440608074044,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":181.99,"dividendRate":0.022481,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.048949,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":181.99,"auctionPrice":185,"auctionVolume":50767,"auctionTime":1791413954668,"referenceTime":1791369003092,"auction":1,"marketStatus":"盘前竞价","timestamp":1791413954668}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.684231,"volumeRatio":1.048949,"shares":478911979,"dividePrice":4.19401,"high":185,"amplitude":0.025881,"preClose":181.99,"low":180.29,"week52Low":88.83,"pbRate":"4.08","psRate":"3.82","week52High":216.734,"institutionHeld":0,"latestPrice":181.1,"committee":0.357143,"eps":-7.685440608074044,"divideRate":0.023159,"volume":126202,"delay":0,"ttmEps":-7.685440608074044,"open":185,"prevYearClose":168.21,"prevWeekClose":175.35,"prevMonthClose":184.22,"prevQuarterClose":184.22,"fiveDayClose":178.24,"twentyDayClose":169.5,"sixtyDayClose":120.373,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656194823","title":"CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2656194823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656194823?lang=en_us&edition=fundamental","pubTime":"2026-08-02 01:23","pubTimestamp":1785604990,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has drawn fresh attention after reporting positive top-line Phase 3b results for its hereditary angioedema therapy ANDEMBRY in children aged 2 to 11 years, supporting potential expanded pediatric use.\nSee our latest analysis for CSL.\nThe ANDEMBRY update comes as CSL trades at A$123.06, with a 7 day share price return of 7.74% and a year to date share price decline of 28.44%. The 1 year total shareholder return is down 52.25%, pointing to weak long term momentum despite a recent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","CSL.AU","LU1169590202.USD","BK4086","LU1169589451.USD","BK7511","LU0728928796.USD","SG9999004303.SGD","CSL","BK7067","BK7508","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396122","title":"CSL Stock And 2 Australian Dividend Shares Backed By Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396122","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656396122?lang=en_us&edition=fundamental","pubTime":"2026-08-01 00:16","pubTimestamp":1785514612,"startTime":"0","endTime":"0","summary":"With inflation, interest rate questions and energy prices all pulling markets in different directions, many investors are looking for income that feels steadier than short term sentiment. Dividend Powerhouses, sometimes called Dividend Aristocrats, focus on companies with yields above 5% that are covered by earnings, growing and relatively stable. That combination can appeal if you want your portfolio to be paid while you wait for clearer signals from central banks and growth data. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","CSL.AU","XJO.AU","CSL","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655435336","title":"Australian Shares Log Best Month Since February as Rate-hike Worries Ease","url":"https://stock-news.laohu8.com/highlight/detail?id=2655435336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655435336?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:25","pubTimestamp":1785482759,"startTime":"0","endTime":"0","summary":"REFILE-Australian shares log best month since February as rate-hike worries easeRemoves extraneous word from fourth bulletS&P/ASX 200 edges up 0.1% on FridayBenchmark logs best month since FebruaryASX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0654597011.USD","BK7511","LU0612318385.USD","BK4112","SG9999002521.SGD","LU0289960550.SGD","LU0708995401.HKD","LU1309081286.SGD","LU0345780950.USD","LU0171293334.USD","LU0572939691.SGD","LU0955669360.SGD","BK7040","SG9999001143.SGD","LU1023059493.AUD","IE0034235071.USD","LU0572940350.SGD","LU0612318971.USD","LU0672654240.SGD","LU0109391861.USD","BK7129","LU0630314457.HKD","FMG.AU","LU0456854461.SGD","WOW.AU","LU0264606111.USD","LU0175139822.USD","RIO.AU","LU0330918003.SGD","BHP.AU","LU0266512127.USD","LU0511384066.AUD","LU0971552830.HKD","LU1302929846.USD","BK7507","FDIQ","MSCI","LU0345777147.USD","RIO.UK","LU0390134368.USD","BK4585","IE00BQJZX424.USD","LU0971552673.USD","IE00B3M56506.USD","LU1046248800.SGD","LU2265009873.SGD","LU0320765059.SGD","LU1078025761.USD","CSL.AU","LU0831103253.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655809269","title":"CSL Stock And QBE Shares For Dividend Income Above 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655809269","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655809269?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:14","pubTimestamp":1785420860,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses with 5%+ yields and solid coverage can be especially appealing when global growth looks mixed, inflation stays uneven, and central banks keep investors guessing on rates. Reliable income from well covered and stable dividends can help smooth out some of that noise and give you a clearer sense of what you are getting paid to wait. This article focuses on three stocks from the Dividend Powerhouses screener that combine higher yields with a history of maintaining and growing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VIG","BGLD","JDST","CSL","PPI","GDXJ","AAAU","EVN.AU","DULL","GOAU","SGDM","SHNY","IGLD","DGP","PHYS","IAU","GLTR","GDX","UYM","GBUG","FGDL","CSL.AU","BTGD","GLL","JNUG","XME","DZZ","IAUM","GDXY","RING","GDXD","GLDY","CEF","BEGS","DGZ","GDXU","DUST","KGLD","USG","SGOL","OUNZ","QBE.AU","BAR","DBC","IAUI","PICK","YGLD","GLDM","GOLY","UGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655296468","title":"Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2655296468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655296468?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:27","pubTimestamp":1785382062,"startTime":"0","endTime":"0","summary":"CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.\nThe company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.\nWe’ll now...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","BK7508","LU0728928796.USD","BK7067","LU1169589451.USD","BK7501","BK4086","SGXZ23171101.USD","CSL","SG9999004303.SGD","BK7511","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655818139","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655818139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655818139?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:32","pubTimestamp":1785349969,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsJuly 30 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**9,038.6090.80NZX 50**13,976.67114.74DJIA51,932.67-814.65NIKKEI**61,434.19-930.73Nasdaq24,779.13","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V1ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSCI","LU2095319765.USD","LU0289739343.SGD","LU0161305163.EUR","LU0898667661.SGD","RIO.UK","LU0831103253.SGD","LU0654597011.USD","BK5111","BK7095","LU0955669360.SGD","LU0971552673.USD","RIO.AU","LU1267930730.SGD","LU0390134368.USD","LU1481600234.SGD","LU2210149790.SGD","FDIQ","IE0034235071.USD","BK7507","LU0572939691.SGD","LU2265009873.SGD","LU0345780950.USD","LU0264606111.USD","BK4112","LU0456854461.SGD","BK7501","LU0289960550.SGD","LU0266512127.USD","LU0266512473.USD","LU0320765059.SGD","LU0345777147.USD","LU0572940350.SGD","LU1130305938.SGD","LU1309081286.SGD","CSL.AU","LU0955648018.USD","LU1064927863.SGD","LU0345781412.USD","LU0011963245.USD","SG9999002521.SGD","LU0171293334.USD","LU0345777659.USD","LU1804176565.USD","BK4585","IE00B3M56506.USD","LU1023059493.AUD","SG9999001143.SGD","LU0612318971.USD","LU0708995401.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830439","title":"ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830439?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:58","pubTimestamp":1785293913,"startTime":"0","endTime":"0","summary":"Healthcare stocks jumped nearly 4%, leading a broad-based rally at midday Wednesday.CSL  gained almost 7% in recent trade following news that it will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process.Meanwhile, the financial sector edged up nearly 1%.Commonwealth Bank  shares inched up in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CBA.AU","XLV","XBI","BK4137","BK4585","BK4581","DBB","BK7067","BK4588","BK7135","HCSG","BK7508","LU0029874061.USD","LU0128526141.USD","BK7511","BK7501","LABU","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783450","title":"Australia's CSL Rises on Launching Trials for Patented Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783450","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783450?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:54","pubTimestamp":1785286492,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises on launching trials for patented manufacturing process** Shares of biotechnology major CSLCSL.AXrise 5.6% to A$126.59, their highest since July 9** Stock on track for best d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7508","BK7501","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655083457","title":"CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655083457","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655083457?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:53","pubTimestamp":1785286428,"startTime":"0","endTime":"0","summary":"CSL  will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process, according to a Wednesday Australian bourse filing.The company said it expects clinical activities to start in mid-2027.The process enables greater production of immunoglobulin from the same base amount of plasma, per the filing.The company said it will obtain clinical evidence to support and finalize regulatory approval processes for Horizon 2 after its engagements with the US Food and Drug Administration and European Medicines Agency.CSL's shares rose nearly 6% in recent trading on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK7501","BK7067","LU0728928796.USD","LU1169590202.USD","CSL","CSL.AU","LU1169589451.USD","BK7511","SGXZ23171101.USD","BK4086","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137947072","title":"Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1137947072","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137947072?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:14","pubTimestamp":1785284061,"startTime":"0","endTime":"0","summary":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655883986","title":"Horizon 2 Technology Enables Greater Immunoglobulin Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2655883986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655883986?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","CSL.AU","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878839","title":"To Launch Clinical Trials for Horizon 2 Immunoglobulin Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878839?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839865","title":"CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839865?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839820","title":"To Seek FDA and Ema Approval for Horizon 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839820?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655398668","title":"CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655398668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655398668?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","CSL.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655383987","title":"To Commence Horizon 2 Clinical Activities in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383987?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885173","title":"ASX Dividend Stocks For Steady Income in Uncertain Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885173","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885173?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:24","pubTimestamp":1785245055,"startTime":"0","endTime":"0","summary":"With inflation signals mixed, central banks cautious and bond yields reacting to every new headline, many investors are looking for steadier income from their portfolios. That is where the Dividend Powerhouses screener comes in. It focuses on companies offering more than a 5% dividend yield that is covered, growing and stable, which can help you keep cash flow coming even as markets adjust to changing energy costs, policy risks and shifting trade patterns. In this article you will see three...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VIG","GBUG","BK7104","BK4535","CSL.AU","BK7506","BK4588","QBE.AU","BK7034","BK4585","PMDE","VOTE","BEGS","BK7511","BK7067","GOAU","PICK","BK7501","EVN.AU","XME","CEF","UYM","BK7508","DECU","GLTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654022877","title":"CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry","url":"https://stock-news.laohu8.com/highlight/detail?id=2654022877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654022877?lang=en_us&edition=fundamental","pubTime":"2026-07-28 09:52","pubTimestamp":1785203526,"startTime":"0","endTime":"0","summary":"CSL's  Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","BK7508","LU0728928796.USD","BK7501","CSL","LU1169589451.USD","SG9999004303.SGD","BK7511","BK4086","SGXZ23171101.USD","LU1169590202.USD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654671048","title":"Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2654671048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654671048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654304862","title":"CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654304862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654304862?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}